EP1109582A4 - Verfahren zur verstärkung und beschränkung der genexpression - Google Patents

Verfahren zur verstärkung und beschränkung der genexpression

Info

Publication number: EP1109582A4
Authority: EP; European Patent Office
Prior art keywords: genes; enhance; methods; confine; expression
Prior art date: 1998-08-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP99943819A

Other languages

English (en)

French (fr)

Other versions

EP1109582A1 (de

Inventor

Yuen Kai Fung

Charles Gomer

Ang Anne T

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Research Development Foundation

Original Assignee

Research Development Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-18

Filing date

1999-08-18

Publication date

2004-11-03

1999-08-18 Application filed by Research Development Foundation filed Critical Research Development Foundation

2001-06-27 Publication of EP1109582A1 publication Critical patent/EP1109582A1/de

2004-11-03 Publication of EP1109582A4 publication Critical patent/EP1109582A4/de

Status Withdrawn legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Marine Sciences & Fisheries (AREA)
Oncology (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP99943819A 1998-08-18 1999-08-18 Verfahren zur verstärkung und beschränkung der genexpression Withdrawn EP1109582A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9694798P	1998-08-18	1998-08-18
US96947P		1998-08-18
PCT/US1999/019095 WO2000010612A1 (en)	1998-08-18	1999-08-18	Methods to enhance and confine expression of genes

Publications (2)

Publication Number	Publication Date
EP1109582A1 EP1109582A1 (de)	2001-06-27
EP1109582A4 true EP1109582A4 (de)	2004-11-03

Family

ID=22259886

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP99943819A Withdrawn EP1109582A4 (de)	1998-08-18	1999-08-18	Verfahren zur verstärkung und beschränkung der genexpression

Country Status (11)

Country	Link
EP (1)	EP1109582A4 (de)
JP (1)	JP2002523032A (de)
KR (1)	KR20020013463A (de)
CN (1)	CN1321093A (de)
AU (1)	AU763183B2 (de)
CA (1)	CA2340929A1 (de)
IL (1)	IL141473A0 (de)
NZ (1)	NZ509966A (de)
RU (1)	RU2226108C2 (de)
WO (1)	WO2000010612A1 (de)
ZA (1)	ZA200101207B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1534839A1 (de) *	2002-08-09	2005-06-01	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Blockierte tetracyclin(derivate), ihre herstellung und ihre verwendung zur photoaktivierten genexpression
KR20030019282A (ko) *	2002-11-27	2003-03-06	김상태	βAPP의 C말단 pCT105 원격제어에 의한 치매발병 유도 세포주 개발
CA2600882C (en)	2005-03-16	2013-02-26	Metabolix, Inc.	Chemically inducible expression of biosynthetic pathways
BR112012010755A2 (pt) *	2009-11-05	2015-09-22	Proyecto Biomedicina Cima Sl	constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
CN101892256B (zh) *	2010-01-27	2012-05-09	中国农业科学院北京畜牧兽医研究所	一种培育猪生长激素表达量增强的转基因动物的方法
BR112014002817A2 (pt)	2011-08-08	2021-09-08	Curelab Oncology Inc	Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
CN102786599B (zh) *	2012-08-01	2014-01-15	中国农业科学院作物科学研究所	水稻转录因子Os05g39950基因的应用
AU2014369861B2 (en)	2013-12-29	2018-09-13	Curelab Oncology, Inc.	Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
CN105925609B (zh) *	2016-07-14	2019-01-08	中国医学科学院输血研究所	带有标记基因的Tet-on诱导过表达的重组载体及构建方法
CN110016464A (zh) *	2018-01-08	2019-07-16	张晋宇	用于筛选抗肿瘤物质的系统及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996027021A1 (en) *	1995-03-01	1996-09-06	Cornell Research Foundation, Inc.	Interdependent adenoviral vectors and methods of using same
WO1998006864A2 (en) *	1996-08-15	1998-02-19	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5891718A (en) *	1996-03-27	1999-04-06	Vical Incorporated	Tetracycline inducible/repressible systems

1999
- 1999-08-18 KR KR1020017002037A patent/KR20020013463A/ko not_active Ceased
- 1999-08-18 CN CN99811269A patent/CN1321093A/zh active Pending
- 1999-08-18 CA CA002340929A patent/CA2340929A1/en not_active Abandoned
- 1999-08-18 IL IL14147399A patent/IL141473A0/xx unknown
- 1999-08-18 WO PCT/US1999/019095 patent/WO2000010612A1/en not_active Ceased
- 1999-08-18 NZ NZ509966A patent/NZ509966A/en unknown
- 1999-08-18 JP JP2000565932A patent/JP2002523032A/ja active Pending
- 1999-08-18 AU AU56845/99A patent/AU763183B2/en not_active Ceased
- 1999-08-18 EP EP99943819A patent/EP1109582A4/de not_active Withdrawn
- 1999-08-18 RU RU2001107251/15A patent/RU2226108C2/ru not_active IP Right Cessation
2001
- 2001-02-13 ZA ZA200101207A patent/ZA200101207B/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996027021A1 (en) *	1995-03-01	1996-09-06	Cornell Research Foundation, Inc.	Interdependent adenoviral vectors and methods of using same
WO1998006864A2 (en) *	1996-08-15	1998-02-19	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HALLAHAN D E ET AL: "SPATIAL AND TEMPORAL CONTROL OF GENE THERAPY USING IONIZING RADIATION", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 1, no. 8, August 1995 (1995-08-01), pages 786 - 791, XP000857200, ISSN: 1078-8956 *
MAUCERI H J ET AL: "TUMOR NECROSIS FACTOR ALPHA(TNT-ALPHA) GENE THERAPY TARGETED BY IONIZING RADIATION SELECTIVELY DAMAGES TUMOR VASCULATURE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 1996, pages 4311 - 4314, XP002936211, ISSN: 0008-5472 *
See also references of WO0010612A1 *
WEICHSELBAUM R R ET AL: "GENE THERAPY TARGETED BY RADIATION PREFERENTIALLY RADIOSENSITIZES TUMOR CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, 15 August 1994 (1994-08-15), pages 4266 - 4269, XP002932030, ISSN: 0008-5472 *

Also Published As

Publication number	Publication date
ZA200101207B (en)	2007-01-31
RU2226108C2 (ru)	2004-03-27
NZ509966A (en)	2003-07-25
AU5684599A (en)	2000-03-14
CA2340929A1 (en)	2000-03-02
CN1321093A (zh)	2001-11-07
JP2002523032A (ja)	2002-07-30
KR20020013463A (ko)	2002-02-20
WO2000010612A1 (en)	2000-03-02
AU763183B2 (en)	2003-07-17
EP1109582A1 (de)	2001-06-27
IL141473A0 (en)	2002-03-10

Legal Events

Date	Code	Title	Description
2001-05-11	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-06-27	17P	Request for examination filed	Effective date: 20010224
2001-06-27	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-06-27	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2004-11-03	A4	Supplementary search report drawn up and despatched	Effective date: 20040921
2005-06-08	17Q	First examination report despatched	Effective date: 20050421
2006-03-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2006-05-10	18D	Application deemed to be withdrawn	Effective date: 20051103

Publication	Publication Date	Title
PL316200A1 (en)	1996-12-23	Co-ordinated expression of genes in vivo
HUP0102598A3 (en)	2003-03-28	Expression of trehalose biosynthetic genes in plants
PL340760A1 (en)	2001-02-26	Genes of desaturase and their application
HUP0103329A3 (en)	2003-09-29	Expression and export of angiostatin and endostatin as immunofusis
HUP0200773A3 (en)	2003-04-28	Methods of inducing cacer cell death and tumor regression
IL131486A0 (en)	2001-01-28	Gene sequencer and methods
AP2000001762A0 (en)	2000-03-31	Method of delivering genes to antigen presenting cells of the skin
AU2001292842A1 (en)	2002-04-02	Compositions and methods relating to prostate specific genes and proteins
GB9706381D0 (en)	1997-05-14	Improvements relating to the specificity of gene expression
EP1109582A4 (de)	2004-11-03	Verfahren zur verstärkung und beschränkung der genexpression
HUP0302908A3 (en)	2004-11-29	Genes and methods for manipulation of growth
AU2002245031A1 (en)	2002-07-24	Compositions and methods relating to prostate specific genes and proteins
PL352326A1 (en)	2003-08-11	Noval vegetable genes and use of same
HUP0204093A3 (en)	2004-10-28	Sorghum dwarfing genes and methods of use
AU2584699A (en)	1999-08-23	Immediate early genes and methods of use therefor
AU9221098A (en)	1999-03-22	Selective expression of genes in plants
AU2002217991A1 (en)	2002-06-03	Compositions and methods relating to prostate specific genes and proteins
GB9721075D0 (en)	1997-12-03	Materials and methods relating to the stimulation of cells
AU1576501A (en)	2001-05-08	Methods to enhance and confine gene expression in cancer therapy
GB9904802D0 (en)	1999-04-28	Improvements in or relating to an item of headgear
AU4459100A (en)	2000-11-10	Cell cycle genes and methods of use
AU2002241557A1 (en)	2002-06-03	Compositions and methods relating to prostate specific genes and proteins
AU6387699A (en)	2000-04-03	Rac-like genes and methods of use
EP1210111A4 (de)	2004-07-21	Dna des gamma-herpesvirus und methoden zu dessen nutzung
AU2002239412A1 (en)	2002-06-03	Compositions and methods relating to prostate specific genes and proteins